Priv.-Doz. Dr. med. Hela-F. Petereit

Publikationsverzeichnis und Buchbeiträge

Publikationsverzeichnis

1: Rubbert-Roth A, Petereit HF. [Nervous system side effects of disease modifying treatments of rheumatoid arthritis]. Z Rheumatol. 2012 Sep;71(7):572-82. German. PubMed PMID: 22930108.

2: Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 2011 Aug 30;77(9):835-43. Epub 2011 Aug 17. Erratum in: Neurology. 2011 Sep 27;77(13):1317. PubMed PMID: 21849647.

3: Petereit HF, Reske D, Tumani H, Jarius S, Markus Leweke F, Woitalla D, Pfister HW, Rubbert A. Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol. 2010 Nov;257(11):1855-63. Epub 2010 Jun 17. PubMed PMID: 20556411.

4: Reske D, Thomas AV, Petereit HF, Fink GR, Schroeter M. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors. Neuroimmunomodulation. 2009;16(6):385-91. Epub 2009 Jul 17. PubMed PMID: 19609087.

5: Multiple Sclerosis Therapy Consensus Group (MSTCG), Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008 Oct;255(10):1449-63. Epub 2008 Oct 29. PubMed PMID: 19005625.

6: Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009 Feb;15(2):189-92. Epub 2008 Oct 29. PubMed PMID: 18971221.

7: Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, Petereit HF, Maurer M, Tumani H, Vincent A, Eichhorn P, Wildemann B, Wick M, Voltz R. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1134-6. Epub 2008 Feb 12. PubMed PMID: 18270237.

8: Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand. 2008 Jun;117(6):399-403. Epub 2007 Nov 20. PubMed PMID: 18031564.

9: Mehler K, Emmel M, Petereit HF, Sprüth A, Dröge A, Brockmeier K. [Sensorineural loss of hearing in lower registers as the main symptom of Lyme disease]. HNO. 2007 Dec;55(12):961-3. German. PubMed PMID: 17103202.

10: Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schröder J, Schönknecht P, Zimmermann K, Hampel H, Bürger K, Otto M, Haustein S, Herzog K, Dannenberg R, Wurster U, Bibl M, Maler JM, Reubach U, Kornhuber J, Wiltfang J. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett. 2006 Nov 27;409(1):1-4. Epub 2006 Oct 11. PubMed PMID: 17045397.

11: Reske D, Pukrop R, Scheinig K, Haupt WF, Petereit HF. [Measuring fatigue in patients with multiple sclerosis with standardized methods in German speaking areas]. Fortschr Neurol Psychiatr. 2006 Sep;74(9):497-502. German. PubMed PMID: 16947099.

12: Bosche B, Dohmen C, Impekoven P, Zaro-Weber O, Reske D, Rubbert A, Jacobs AH, Petereit HF. Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease. Acta Neurol Scand. 2006 Jun;113(6):433-6. Erratum in: Acta Neurol Scand. 2009 Dec;120(6):453. Weber, O Z [corrected to Zaro-Weber, O]. PubMed PMID: 16674611.

13: Reske D, Haupt WF, Petereit HF. Gender change and its impact on the course of multiple sclerosis. Acta Neurol Scand. 2006 May;113(5):347-9. Erratum in: Acta Neurol Scand. 2006 Aug;114(2):144. Haupt, WF [added]; Petereit, HF [added]. PubMed PMID: 16629772.

14: Thomas AV, Klein JC, Brockhaus-Dumke A, Heiss WD, Jacobs AH, Petereit HF. [Fatal familial insomnia: case presentation and discussion of typical clinical and imaging findings]. Nervenarzt. 2006 Jun;77(6):711-5. German. PubMed PMID: 16550412.

15: Petereit HF, Seifert H, Geiss HK, Wildemann B. [Detecting infectious agents in central nervous system inflammation by cerebrospinal fluid analysis]. Nervenarzt. 2006 Apr;77(4):481-92; quiz 493-4. German. PubMed PMID: 16496104.

16: Lensch E, Matzke M, Petereit HF, Scherer P, Schramm S, Calabrese P. Identification and management of cognitive disorders in multiple sclerosis--a consensus approach. J Neurol. 2006 Feb;253 Suppl 1:I29-31. PubMed PMID: 16477483.

17: Petereit HF, Reske D, Pukrop R, Maas-Enriquez M, Japp G, Jongen PJ, Kölmel HW, Merkelbach S, Hartung HP, Heiss WD, Hommes OR. No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis. Mult Scler. 2006 Feb;12(1):66-71. PubMed PMID: 16459721.

18: Petereit HF, Rubbert A. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch Neurol. 2005 Oct;62(10):1641-2; author reply 1642. PubMed PMID: 16216954.

19: Reske D, Petereit HF, Heiss WD. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system--value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand. 2005 Oct;112(4):207-13. Review. PubMed PMID: 16146488.

20: Galldiks N, Petereit HF, Haupt WF. [Complications and diagnostic limitations of chronic meningitis]. Dtsch Med Wochenschr. 2005 Jul 8;130(27):1633-6. German. PubMed PMID: 15988661.

21: Petereit HF, Reske D. Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res. 2005 Jun 27;2:3. PubMed PMID: 15982411; PubMed Central PMCID: PMC1173126.

22: Nolden S, Casper C, Kuhn A, Petereit HF. Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. Mult Scler. 2005 Apr;11(2):245-8. PubMed PMID: 15794402.

23: Rieckmann P, Toyka KV, Bassetti C, Beer K, Beer S, Buettner U, Chofflon M, Götschi-Fuchs M, Hess K, Kappos L, Kesselring J, Goebels N, Ludin HP, Mattle H, Schluep M, Vaney C, Baumhackl U, Berger T, Deisenhammer F, Fazekas F, Freimüller M, Kollegger H, Kristoferitsch W, Lassmann H, Markut H, Strasser-Fuchs S, Vass K, Altenkirch H, Bamborschke S, Baum K, Benecke R, Brück W, Dommasch D, Elias WG, Gass A, Gehlen W, Haas J, Haferkamp G, Hanefeld F, Hartung HP, Heesen C, Heidenreich F, Heitmann R, Hemmer B, Hense T, Hohlfeld R, Janzen RW, Japp G, Jung S, Jügelt E, Koehler J, Kölmel W, König N, Lowitzsch K, Manegold U, Melms A, Mertin J, Oschmann P, Petereit HF, Pette M, Pöhlau D, Pohl D, Poser S, Sailer M, Schmidt S, Schock G, Schulz M, Schwarz S, Seidel D, Sommer N, Stangel M, Stark E, Steinbrecher A, Tumani H, Voltz R, Weber F, Weinrich W, Weissert R, Wiendl H, Wiethölter H, Wildemann U, Zettl UK, Zipp F, Zschenderlein R, Izquierdo G, Kirjazovas A, Packauskas L, Miller D, Koncan Vracko B, Millers A, Orologas A, Panellus M, Sindic CJ, Bratic M, Svraka A, Vella NR, Stelmasiak Z, Selmaj K, Bartosik-Psujik H, Mitosek-Szewczyk K, Belniak E, Mochecka A, Bayas A, Chan A, Flachenecker P, Gold R, Kallmann B, Leussink V, Mäurer M, Ruprecht K, Stoll G, Weilbach FX; Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol. 2004 Nov;251(11):1329-39. Review. PubMed PMID: 15592728.

24: Brettschneider J, Riepe MW, Petereit HF, Ludolph AC, Tumani H. Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus? J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1614-6. PubMed PMID: 15489398; PubMed Central PMCID: PMC1738804.

25: Petereit HF, Perniok A. Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies. Neurology. 2004 Aug 24;63(4):762-3; author reply 762-3. PubMed PMID: 15326273.

26: Reske D, Petereit HF. [Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters]. Nervenarzt. 2004 Oct;75(10):945-52. Review. German. PubMed PMID: 15060767.

27: Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand. 2004 Jan;109(1):66-70. PubMed PMID: 14653853.

28: Hartmann P, Herholz K, Salzberger B, Petereit HF. Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma. Ann Hematol. 2004 Apr;83(4):212-7. Epub 2003 Nov 26. PubMed PMID: 14648028.

29: Reske D, Schoppe S, Broicher C, Petereit HF. The immunomodulatory properties of in vitro immunoglobulins are dose-dependent. Acta Neurol Scand. 2003 Oct;108(4):267-73. PubMed PMID: 12956861.

30: Petereit HF, Lindemann H, Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler. 2003 Feb;9(1):16-20. PubMed PMID: 12617262.

31: Petereit HF, Pukrop R, Fazekas F, Bamborschke SU, Röpele S, Kölmel HW, Merkelbach S, Japp G, Jongen PJ, Hartung HP, Hommes OR. Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. J Neurol Sci. 2003 Feb 15;206(2):209-14. PubMed PMID: 12559513.

32: Petereit HF, Nolden S, Schoppe S, Bamborschke S, Pukrop R, Heiss WD. Low interferon gamma producers are better treatment responders: a two-year follow-up of interferon beta-treated multiple sclerosis patients. Mult Scler. 2002 Dec;8(6):492-4. PubMed PMID: 12474989.

33: Petereit HF, Ruffing G, Weilbach FX, Zessack N, Zettl UK. [DRGs as future reimbursement system for hospital services exemplified by multiple sclerosis]. Nervenarzt. 2002 Aug;73(8):785-91. German. PubMed PMID: 12242969.

34: Petereit HF, Heiss WD. New diagnostic criteria for multiple sclerosis. Ann Neurol. 2002 Apr;51(4):533-4; author reply 534. PubMed PMID: 11921064.

35: Petereit HF, Bachmann G, Nekic M, Althaus H, Pukrop R. A new nephelometric assay for beta-trace protein (prostaglandin D synthase) as an indicator of liquorrhoea. J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):347-51. PubMed PMID: 11511708; PubMed Central PMCID: PMC1737575.

36: Petereit HF, Impekoven P, Bamborschke S, Pawlik G. [Nuclear magnetic resonance tomography in multiple sclerosis]. Dtsch Med Wochenschr. 2000 Nov 10;125(45):1375-80. Review. German. PubMed PMID: 11109427.

37: Petereit HF, Richter N, Pukrop R, Bamborschke S. Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients. Mult Scler. 2000 Feb;6(1):19-23. PubMed PMID: 10694841.

38: Petereit HF, Bamborschke S, Esse AD, Heiss WD. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis. Mult Scler. 1997 Jun;3(3):180-3. PubMed PMID: 9310963.

39: Petereit HF, Bamborschke S, Lanfermann H. Acute transverse myelitis caused by herpes simplex virus. Eur Neurol. 1996;36(1):52-3. PubMed PMID: 8719652.

nach oben

Buchbeiträge

1. Petereit HF, Kracht L, von Smekal U, Heiss WD. Subakut sklerosierende Panenzephalitis. Bildgebung in der Neuroimmunologie. Thieme-Verlag Stuttgart, im Druck

2. Petereit HF: Immuntherapeutika. Copaxone. In Fricke, U, Klaus, W: Neue Arzneimittel 2001. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, im Druck

3. Petereit HF: Psychostimulantien. Modafinil. In Fricke, U, Klaus, W: Neue Arzneimittel 1999, Band 13. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

4. Petereit HF: Hypnotika. Sonata. In Fricke, U, Klaus, W: Neue Arzneimittel 1999, Band 13. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

5. Petereit HF, Szelies B: Antiepileptika. Gabitril. In Fricke, U, Klaus, W: Neue Arzneimittel 1999, Band 13. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

6. Petereit HF, Szelies B: Antiepileptika. Keppra. In Fricke, U, Klaus, W: Neue Arzneimittel 1999, Band 13. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

7. Petereit HF, Szelies B: Antiepileptika. Topamax. In Fricke, U, Klaus, W: Neue Arzneimittel 1999, Band 13. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

8. Petereit HF, Szelies B: Antiepileptika. Trileptal. In Fricke, U, Klaus, W: Neue Arzneimittel 1999, Band 13. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.

9. Petereit HF, Pawlik G: Parkinsonmittel und andere Mittel gegen extrapyramidale Störungen. Budipin. In: Fricke U, Klaus W: Neue Arzneimittel 1998. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

10. Petereit HF, Pawlik G: Parkinsonmittel und andere Mittel gegen extrapyramidale Störungen. Pramipexol. In: Fricke U, Klaus W: Neue Arzneimittel 1998. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

11. Petereit HF, Pawlik G: Parkinsonmittel und andere Mittel gegen extrapyramidale Störungen. Entacapone. In: Fricke U, Klaus W: Neue Arzneimittel 1998. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

12. Petereit HF, Pawlik G: Parkinsonmittel und andere Mittel gegen extrapyramidale Störungen. Ropinirol. In: Fricke U, Klaus W: Neue Arzneimittel 1998. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart

13. Bamborschke S, Petereit HF, Nolden S: Supplementäre Aktivierungs- und Destruktionsmarker. In: Zettl, UK, Lehmitz R, Mix E (Hrsg.): Klinische Liquordiagnostik. Walter de Gruyter, Berlin, New York 2003.

14. Petereit HF, Bamborschke S: Immuntherapeutika und Zytokine. Zytokine. Betaferon. In: Fricke U, Klaus W: Neue Arzneimittel 1997. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart

15. Petereit HF, Nolden S: Immuntherapeutika und Zytokine. Zytokine. Rebif und Avonex. In: Fricke U, Klaus W: Neue Arzneimittel 1997. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart

16. Petereit HF: Neuropathiepräparate und andere neurotrope Mittel. Riluzol. In: Fricke U, Klaus W: Neue Arzneimittel 1997. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart

nach oben